200 related articles for article (PubMed ID: 35029286)
1. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
4. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
[TBL] [Abstract][Full Text] [Related]
5. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer.
Kim L; Park SA; Park H; Kim H; Heo TH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445405
[TBL] [Abstract][Full Text] [Related]
7. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
9. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
10. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
11. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
12. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
13. Discovery of bazedoxifene analogues targeting glycoprotein 130.
Song D; Yu W; Ren Y; Zhu J; Wan C; Cai G; Guo J; Zhang W; Kong L
Eur J Med Chem; 2020 Aug; 199():112375. PubMed ID: 32388278
[TBL] [Abstract][Full Text] [Related]
14. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
15. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
16. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
17. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
Zhang R; Roque DM; Reader J; Lin J
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
